FDA Inspection
Armstrong Pharmaceuticals, Inc.Armstrong Pharmaceuticals, Inc. – FDA Inspection, May 8, 2026
Record Details
This FDA Inspection record concerns Armstrong Pharmaceuticals, Inc., with an inspection on May 8, 2026, issued by the New England District Office, covering human drugs.
View Company Profile
ID · 225f3f63-e9d3-42cd-af9d-df3e59ee2d53
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1316472
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 211.68(b)Computer control of master formula records
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Armstrong Pharmaceuticals, Inc.
10| Date | Classification | Office | Project area |
|---|---|---|---|
| July 19, 2024 | VAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| July 14, 2021 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 3, 2014 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| October 5, 2012 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 14, 2012 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Armstrong Pharmaceuticals, Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.